Intralesional MMR Vaccine Shows Promise for Treating Resistant Pediatric Warts

Written By :  Medha Baranwal
Medically Reviewed By :  Dr. Kamal Kant Kohli
Published On 2023-09-15 04:15 GMT   |   Update On 2024-02-12 19:30 GMT
Advertisement

USA: Warts are a common skin condition, especially among children, and while various treatments are available, some warts can be particularly stubborn and resistant to conventional therapies. A recent retrospective study has explored the potential of using the measles, mumps, and rubella (MMR) vaccine as an alternative treatment for pediatric warts that have failed to respond to initial therapy with Candida antigen.

The study included 51 pediatric patients with warts that had proven resistant to intralesional Candida antigen therapy. These patients were then treated with intralesional injections of the MMR vaccine. The results were encouraging, with 15.5% of the patients experiencing complete resolution of their warts. Additionally, 12% had a near-complete resolution, and 37% showed partial improvement.

One interesting finding from the study was that age seemed to play a role in treatment response. Patients under the age of 12 were more likely to respond positively to the MMR vaccine treatment. However, the number of MMR treatments did not significantly affect treatment response.

While this study has its limitations, such as its retrospective nature and relatively small sample size, it suggests that the intralesional MMR vaccine could be a viable and effective treatment option for pediatric warts that do not respond to conventional therapies. The findings also highlight the importance of exploring alternative treatments for stubborn skin conditions, particularly in cases where existing therapies have been ineffective.

This study suggests that the intralesional MMR vaccine could offer hope for patients dealing with stubborn pediatric warts. It emphasises the importance of exploring alternative treatments when initial therapies fail and highlights the potential benefits of early intervention, especially in younger patients. Further research may provide more insights into optimising this approach for the effective management of warts in children.

Reference:

Ulschmid, C. M., Patel, J., Pan, A. Y., Liegl, M., & Holland, K. E. (2023). Intralesional measles, mumps, and rubella vaccine after failure of intralesional Candida antigen for the treatment of recalcitrant pediatric warts. Pediatric Dermatology. https://doi.org/10.1111/pde.15415


Tags:    
Article Source : Pediatric Dermatology

Disclaimer: This website is primarily for healthcare professionals. The content here does not replace medical advice and should not be used as medical, diagnostic, endorsement, treatment, or prescription advice. Medical science evolves rapidly, and we strive to keep our information current. If you find any discrepancies, please contact us at corrections@medicaldialogues.in. Read our Correction Policy here. Nothing here should be used as a substitute for medical advice, diagnosis, or treatment. We do not endorse any healthcare advice that contradicts a physician's guidance. Use of this site is subject to our Terms of Use, Privacy Policy, and Advertisement Policy. For more details, read our Full Disclaimer here.

NOTE: Join us in combating medical misinformation. If you encounter a questionable health, medical, or medical education claim, email us at factcheck@medicaldialogues.in for evaluation.

Our comments section is governed by our Comments Policy . By posting comments at Medical Dialogues you automatically agree with our Comments Policy , Terms And Conditions and Privacy Policy .

Similar News